Obsidian Therapeutics (NASDAQ:OBX) Short Interest Up 125.6% in August

Obsidian Therapeutics (NASDAQ:OBX) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 81,457 shares, a growth of 125.6% from the August 15th total of 36,102 shares. Based on an average daily volume of 227,768 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the company’s shares are short sold.

Obsidian Therapeutics Price Performance

NASDAQ:OBX traded up $0.81 on Monday, reaching $18.61. 67,570 shares of the stock traded hands, compared to its average volume of 190,342. Obsidian Therapeutics has a 1-year low of $14.57 and a 1-year high of $49.97.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Piper Sandler began coverage on shares of Obsidian Therapeutics in a report on Wednesday, August 5th. They set an “overweight” rating and a $42.00 price objective for the company. Weiss Ratings assumed coverage on shares of Obsidian Therapeutics in a research note on Wednesday, September 2nd. They set a “sell (d-)” rating for the company. Lifesci Capital initiated coverage on Obsidian Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating and a $43.00 price target on the stock. William Blair started coverage on Obsidian Therapeutics in a report on Wednesday. They set an “outperform” rating for the company. Finally, TD Cowen started coverage on Obsidian Therapeutics in a research report on Thursday, August 6th. They set a “buy” rating for the company. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.50.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.